Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Vaxart
Biotech
HHS delivers stop work order to Atlanta biotech, pulls funding
In June 2024, the government granted GeoVax $24.3 million to run a 10,000-participant phase 2b study for its next-gen COVID vaccine.
Gabrielle Masson
Apr 16, 2025 11:02am
Vaxart lays off staffers after HHS demands halt to vaccine trial
Mar 21, 2025 8:36am
Biopharma largely unfazed by security concerns for JPM25
Jan 17, 2025 11:10am
JPM25, Day 2: Pharma should 'run towards' vaccine conversations
Jan 14, 2025 11:30am
BioMarin hires ex-Roche leader Hubbard as CCO—Chutes & Ladders
Mar 8, 2024 9:30am
Vaxart norovirus vaccine has mixed success in midphase test
Sep 7, 2023 5:31am
